Rheumatoid Arthritis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Rheumatoid Arthritis pipeline constitutes 120+ key companies continuously working towards developing 120+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Rheumatoid Arthritis Overview
Rheumatoid arthritis is a long-term condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. Rheumatoid arthritis is an autoimmune disease in which the immune system (which usually fights infection) attacks the cells that line the joints by mistake, making the joints swollen, stiff and painful.

Rheumatoid arthritis can be difficult to diagnose because many conditions cause joint stiffness and inflammation and there's no definitive test for the condition.

"Rheumatoid Arthritis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years. Rheumatoid Arthritis Key players such as - Landos Biopharma, Biozeus, I-Mab Biopharma, Denali Therapeutics, Oryn Therapeutics, Kymera therapeutics, Hope Biosciences, Beijing Baylx Biotech, Aclaris Therapeutics, Bristol Myers Squibb, AbbVie, AstraZeneca, RemeGen, Jiangsu Hengrui Medicine, SinoMab, and others, are developing therapies for the Rheumatoid Arthritis treatment
• Rheumatoid Arthritis Emerging therapies such as - LABP-69, BZ068, TJ003234, DNL-758, ORTD 1, KT-474, HB-adMSC, hUC-MSC infusion, ATI-450, Branebrutinib, Elsubrutini, AZD9567, RC18, SHR0302, SM03, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
• In September 2017, Jiangsu HengRui Medicine initiated a randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the safety and efficacy of SHR0302 in patients with moderate-to-severe active Rheumatoid Arthritis
• In January 2018, Jiangsu Hengrui Medicine and Arcutis, Inc., exclusive option and license agreement for the development and commercialization of topical applications of Hengrui's investigational drug, SHR0302, for the treatment of dermatology disorders. SHR0302, a highly potent, selective JAK inhibitor, is currently being evaluated in Phase 2 clinical trials for rheumatoid arthritis in China
• In July 2020, Jiangsu HengRui Medicine initiated a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of SHR0302 in moderate-to-severe active Rheumatoid Arthritis subjects with inadequate response to csDMARDs

Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight's Rheumatoid Arthritis Report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• LABP-69: Landos Biopharma
• BZ068: Biozeus
• TJ003234: I-Mab Biopharma
• DNL-758: Denali Therapeutics
• ORTD 1: Oryn Therapeutics
• KT-474: Kymera therapeutics
• HB-adMSC: Hope Biosciences
• hUC-MSC infusion: Beijing Baylx Biotech
• ATI-450: Aclaris Therapeutics
• Branebrutinib: Bristol Myers Squibb
• Elsubrutinib: AbbVie
• AZD9567: AstraZeneca
• RC18: RemeGen
• SHR0302: Jiangsu Hengrui Medicine
• SM03: SinoMab

Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Rheumatoid Arthritis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies at: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders
• Rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis
• Rich emerging Rheumatoid Arthritis pipeline
• Acceptance of biosimilars for treatment of
Rheumatoid Arthritis

Rheumatoid Arthritis Pipeline Market Barriers
• High cost of biologics
• Low adherence to the drugs
• Lack of daily assessment of Rheumatoid Arthritis

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Assessment- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Rheumatoid Arthritis Companies: Landos Biopharma, Biozeus, I-Mab Biopharma, Denali Therapeutics, Oryn Therapeutics, Kymera therapeutics, Hope Biosciences, Beijing Baylx Biotech, Aclaris Therapeutics, Bristol Myers Squibb, AbbVie, AstraZeneca, RemeGen, Jiangsu Hengrui Medicine, SinoMab, and others
• Key Rheumatoid Arthritis Therapies: LABP-69, BZ068, TJ003234, DNL-758, ORTD 1, KT-474, HB-adMSC, hUC-MSC infusion, ATI-450, Branebrutinib, Elsubrutini, AZD9567, RC18, SHR0302, SM03, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Rheumatoid Arthritis Report Introduction
2 Rheumatoid Arthritis Executive Summary
3 Rheumatoid Arthritis Overview
4 Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5 Rheumatoid Arthritis Pipeline Therapeutics
6 Rheumatoid Arthritis Late Stage Products (Phase II/III)
7 Rheumatoid Arthritis Mid Stage Products (Phase II)
8 Rheumatoid Arthritis Early Stage Products (Phase I)
9 Rheumatoid Arthritis Preclinical Stage Products
10 Rheumatoid Arthritis Therapeutics Assessment
11 Rheumatoid Arthritis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Rheumatoid Arthritis Key Companies
14 Rheumatoid Arthritis Key Products
15 Rheumatoid Arthritis Unmet Needs
16 Rheumatoid Arthritis Market Drivers and Barriers
17 Rheumatoid Arthritis Future Perspectives and Conclusion
18 Rheumatoid Arthritis Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Rheumatoid Arthritis Market https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Rheumatoid Arthritis Epidemiology https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.